The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey
Authors
EL-ASHWAH, Shaimaa, Jon SALMANTON-GARCIA, Yavuz M BILGIN, Federico ITRI, Pavel ZAK, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Luisa VERGA, Ali S OMRANI, Maria Gomes da SILVA, Tomas SZOTKOWSKI, Monia MARCHETTI, Caterina BUQUICCHIO, Marcio NUCCI, Martin SCHOENLEIN, Francesca FARINA, Caroline BESSON, Lucia PREZIOSO, Summiya NIZAMUDDIN, Julio DAVILA-VALLS, Sonia MARTIN-PEREZ, Valentina BONUOMO, Van Doesum JAAP, Maria Chiara TISI, Francesco PASSAMONTI, Gustavo-Adolfo MENDEZ, Stef MEERS, Johan MAERTENS, Alberto LOPEZ-GARCIA, Andreas GLENTHOJ, Matteo BONNANI, Ikhwan RINALDI, Irati ORMAZABAL-VELEZ, Jorge LABRADOR, Austin KULASEKARARAJ, Ildefonso ESPIGADO, Fatih DEMIRKAN, De Jonge NICK, Graham P COLLINS, Maria CALBACHO, Ola BLENNOW, Murtadha AL-KHABORI, Tatjana ADZIC-VUKICEVIC, Elena ARELLANO, Bojana MISKOVIC, Milos MLADENOVIC, Anna NORDLANDER, Zdenek RACIL, Emanuele AMMATUNA, Raul CORDOBA, Ditte Stampe HERSBY, Stefanie GRAEFE, Ziad EMARAH, Michaela HANAKOVA, Maria Vittoria SACCHI, Marriyam IJAZ, Laman RAHIMLI, Nunes Rodrigues RAQUEL, Giovanni Paolo Maria ZAMBROTTA, Francesco MARCHESI, Oliver A CORNELY and Livio PAGANO
Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.
EL-ASHWAH, Shaimaa, Jon SALMANTON-GARCIA, Yavuz M BILGIN, Federico ITRI, Pavel ZAK, Barbora WEINBERGEROVÁ, Luisa VERGA, Ali S OMRANI, Maria Gomes da SILVA, Tomas SZOTKOWSKI, Monia MARCHETTI, Caterina BUQUICCHIO, Marcio NUCCI, Martin SCHOENLEIN, Francesca FARINA, Caroline BESSON, Lucia PREZIOSO, Summiya NIZAMUDDIN, Julio DAVILA-VALLS, Sonia MARTIN-PEREZ, Valentina BONUOMO, Van Doesum JAAP, Maria Chiara TISI, Francesco PASSAMONTI, Gustavo-Adolfo MENDEZ, Stef MEERS, Johan MAERTENS, Alberto LOPEZ-GARCIA, Andreas GLENTHOJ, Matteo BONNANI, Ikhwan RINALDI, Irati ORMAZABAL-VELEZ, Jorge LABRADOR, Austin KULASEKARARAJ, Ildefonso ESPIGADO, Fatih DEMIRKAN, De Jonge NICK, Graham P COLLINS, Maria CALBACHO, Ola BLENNOW, Murtadha AL-KHABORI, Tatjana ADZIC-VUKICEVIC, Elena ARELLANO, Bojana MISKOVIC, Milos MLADENOVIC, Anna NORDLANDER, Zdenek RACIL, Emanuele AMMATUNA, Raul CORDOBA, Ditte Stampe HERSBY, Stefanie GRAEFE, Ziad EMARAH, Michaela HANAKOVA, Maria Vittoria SACCHI, Marriyam IJAZ, Laman RAHIMLI, Nunes Rodrigues RAQUEL, Giovanni Paolo Maria ZAMBROTTA, Francesco MARCHESI, Oliver A CORNELY and Livio PAGANO. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2024, vol. 65, No 2, p. 199-208. ISSN 1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2023.2280886.
@article{2369026, author = {ElandAshwah, Shaimaa and SalmantonandGarcia, Jon and Bilgin, Yavuz M and Itri, Federico and Zak, Pavel and Weinbergerová, Barbora and Verga, Luisa and Omrani, Ali S and Silva, Maria Gomes da and Szotkowski, Tomas and Marchetti, Monia and Buquicchio, Caterina and Nucci, Marcio and Schoenlein, Martin and Farina, Francesca and Besson, Caroline and Prezioso, Lucia and Nizamuddin, Summiya and DavilaandValls, Julio and MartinandPerez, Sonia and Bonuomo, Valentina and Jaap, Van Doesum and Tisi, Maria Chiara and Passamonti, Francesco and Mendez, GustavoandAdolfo and Meers, Stef and Maertens, Johan and LopezandGarcia, Alberto and Glenthoj, Andreas and Bonnani, Matteo and Rinaldi, Ikhwan and OrmazabalandVelez, Irati and Labrador, Jorge and Kulasekararaj, Austin and Espigado, Ildefonso and Demirkan, Fatih and Nick, De Jonge and Collins, Graham P and Calbacho, Maria and Blennow, Ola and AlandKhabori, Murtadha and AdzicandVukicevic, Tatjana and Arellano, Elena and Miskovic, Bojana and Mladenovic, Milos and Nordlander, Anna and Racil, Zdenek and Ammatuna, Emanuele and Cordoba, Raul and Hersby, Ditte Stampe and Graefe, Stefanie and Emarah, Ziad and Hanakova, Michaela and Sacchi, Maria Vittoria and Ijaz, Marriyam and Rahimli, Laman and Raquel, Nunes Rodrigues and Zambrotta, Giovanni Paolo Maria and Marchesi, Francesco and Cornely, Oliver A and Pagano, Livio}, article_location = {LONDON}, article_number = {2}, doi = {http://dx.doi.org/10.1080/10428194.2023.2280886}, keywords = {Chronic myeloid leukemia; tirosine kinase inhibitor; COVID-19; SARS-CoV-2; neoplasia; vaccines}, language = {eng}, issn = {1042-8194}, journal = {LEUKEMIA & LYMPHOMA}, title = {The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey}, url = {https://www.tandfonline.com/doi/full/10.1080/10428194.2023.2280886}, volume = {65}, year = {2024} }
TY - JOUR ID - 2369026 AU - El-Ashwah, Shaimaa - Salmanton-Garcia, Jon - Bilgin, Yavuz M - Itri, Federico - Zak, Pavel - Weinbergerová, Barbora - Verga, Luisa - Omrani, Ali S - Silva, Maria Gomes da - Szotkowski, Tomas - Marchetti, Monia - Buquicchio, Caterina - Nucci, Marcio - Schoenlein, Martin - Farina, Francesca - Besson, Caroline - Prezioso, Lucia - Nizamuddin, Summiya - Davila-Valls, Julio - Martin-Perez, Sonia - Bonuomo, Valentina - Jaap, Van Doesum - Tisi, Maria Chiara - Passamonti, Francesco - Mendez, Gustavo-Adolfo - Meers, Stef - Maertens, Johan - Lopez-Garcia, Alberto - Glenthoj, Andreas - Bonnani, Matteo - Rinaldi, Ikhwan - Ormazabal-Velez, Irati - Labrador, Jorge - Kulasekararaj, Austin - Espigado, Ildefonso - Demirkan, Fatih - Nick, De Jonge - Collins, Graham P - Calbacho, Maria - Blennow, Ola - Al-Khabori, Murtadha - Adzic-Vukicevic, Tatjana - Arellano, Elena - Miskovic, Bojana - Mladenovic, Milos - Nordlander, Anna - Racil, Zdenek - Ammatuna, Emanuele - Cordoba, Raul - Hersby, Ditte Stampe - Graefe, Stefanie - Emarah, Ziad - Hanakova, Michaela - Sacchi, Maria Vittoria - Ijaz, Marriyam - Rahimli, Laman - Raquel, Nunes Rodrigues - Zambrotta, Giovanni Paolo Maria - Marchesi, Francesco - Cornely, Oliver A - Pagano, Livio PY - 2024 TI - The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey JF - LEUKEMIA & LYMPHOMA VL - 65 IS - 2 SP - 199-208 EP - 199-208 PB - INFORMA HEALTHCARE SN - 10428194 KW - Chronic myeloid leukemia KW - tirosine kinase inhibitor KW - COVID-19 KW - SARS-CoV-2 KW - neoplasia KW - vaccines UR - https://www.tandfonline.com/doi/full/10.1080/10428194.2023.2280886 N2 - Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients. ER -
EL-ASHWAH, Shaimaa, Jon SALMANTON-GARCIA, Yavuz M BILGIN, Federico ITRI, Pavel ZAK, Barbora WEINBERGEROVÁ, Luisa VERGA, Ali S OMRANI, Maria Gomes da SILVA, Tomas SZOTKOWSKI, Monia MARCHETTI, Caterina BUQUICCHIO, Marcio NUCCI, Martin SCHOENLEIN, Francesca FARINA, Caroline BESSON, Lucia PREZIOSO, Summiya NIZAMUDDIN, Julio DAVILA-VALLS, Sonia MARTIN-PEREZ, Valentina BONUOMO, Van Doesum JAAP, Maria Chiara TISI, Francesco PASSAMONTI, Gustavo-Adolfo MENDEZ, Stef MEERS, Johan MAERTENS, Alberto LOPEZ-GARCIA, Andreas GLENTHOJ, Matteo BONNANI, Ikhwan RINALDI, Irati ORMAZABAL-VELEZ, Jorge LABRADOR, Austin KULASEKARARAJ, Ildefonso ESPIGADO, Fatih DEMIRKAN, De Jonge NICK, Graham P COLLINS, Maria CALBACHO, Ola BLENNOW, Murtadha AL-KHABORI, Tatjana ADZIC-VUKICEVIC, Elena ARELLANO, Bojana MISKOVIC, Milos MLADENOVIC, Anna NORDLANDER, Zdenek RACIL, Emanuele AMMATUNA, Raul CORDOBA, Ditte Stampe HERSBY, Stefanie GRAEFE, Ziad EMARAH, Michaela HANAKOVA, Maria Vittoria SACCHI, Marriyam IJAZ, Laman RAHIMLI, Nunes Rodrigues RAQUEL, Giovanni Paolo Maria ZAMBROTTA, Francesco MARCHESI, Oliver A CORNELY and Livio PAGANO. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey. \textit{LEUKEMIA \&{} LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2024, vol.~65, No~2, p.~199-208. ISSN~1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2023.2280886.